JAK inhibitors show no increased cardiovascular risk in rheumatoid arthritis patients, large international study finds
An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first two years of treatment with Janus kinase inhibitors (JAKi) compared to tumor necrosis factor inhibitors ...